In the realm of testosterone therapy, options abound, offering individuals diverse methods to address hormonal imbalances and associated health concerns. Among these options, testosterone undecanoate emerges as a notable contender, offering both injectable and oral formulations to cater to individual preferences and needs. In this comprehensive guide, we delve into the intricacies of testosterone undecanoate, exploring its mechanisms, therapeutic applications, potential side effects, and considerations for optimal use.
WHAT IS TESTOSTERONE UNDECANOATE?
Testosterone undecanoate, available in injectable and oral forms, offers versatility in testosterone replacement therapy. The injectable variant, commonly prescribed under the brand name Aveed, boasts a long-acting formulation necessitating only five injections annually. Alternatively, oral formulations such as Jatenzo, Kyzatrex, and Tlando provide convenience with twice-daily dosing, catering to individuals seeking an alternative to injections.
TESTOSTERONE UNDECANOATE VS. OTHER FORMS OF T
In comparison to other testosterone formulations, testosterone undecanoate stands out for its extended dosing intervals, requiring fewer injections per year. This advantage is particularly beneficial for individuals averse to frequent injections. Moreover, its availability in oral form distinguishes testosterone undecanoate as a viable option for those seeking alternative routes of administration.
WHAT DOES TESTOSTERONE UNDECANOATE TREAT?
Beyond its role as a “male” sex hormone, testosterone plays a crucial role in various physiological processes for individuals of all genders. Testosterone replacement therapy has demonstrated efficacy in alleviating symptoms of hypogonadism in cisgender men, including mood changes, bone density loss, and sexual dysfunction. Additionally, testosterone therapy has shown promising results in addressing gender dysphoria in transgender men and nonbinary individuals.
WHO SHOULD AVOID TAKING T?
While testosterone therapy offers manifold benefits, certain populations should exercise caution. Older individuals with preexisting medical conditions, such as uncontrolled hypertension, are at heightened risk of adverse effects and should approach testosterone therapy with caution. Furthermore, testosterone therapy is contraindicated in individuals with breast cancer, prostate cancer, and specific hematologic disorders.
POSSIBLE SIDE EFFECTS OF TAKING TESTOSTERONE
Despite its therapeutic potential, testosterone replacement therapy is not without risks. Both injectable and oral formulations carry the risk of side effects, ranging from acne and alopecia to alterations in lipid profiles and blood pressure. Additionally, increased prostate-specific antigen (PSA) levels, albeit rare, may necessitate monitoring due to their potential association with prostate cancer risk.
CONCLUSION
Testosterone undecanoate, whether administered via injections or oral capsules, offers a promising avenue for individuals seeking testosterone replacement therapy. However, consultation with a healthcare provider is imperative to ensure safe and effective treatment tailored to individual needs and circumstances. By partnering with a knowledgeable healthcare provider, individuals can navigate the complexities of testosterone therapy with confidence and clarity.
DISCLAIMER
For personalized medical advice, consultation with a qualified healthcare provider is essential. While the information provided in this guide is grounded in peer-reviewed research and reputable sources, it should not replace professional medical guidance. Readers are encouraged to seek individualized healthcare recommendations based on their specific health concerns and medical history.
Sources:
- Wang C, Nieschlag E, Swerdloff RS, et al. “Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations.” European Urology, vol. 55, no. 1, 2009, pp. 121-130.
- Basaria S. “Male hypogonadism.” The Lancet, vol. 383, no. 9924, 2014, pp. 1250-1263.
- European Medicines Agency. “Aveed – Summary of Product Characteristics.” EMA, 2020, https://www.ema.europa.eu/en/documents/product-information/aveed-epar-product-information_en.pdf.
- Khera M, Crawford D, Morales A, et al. “A new era of testosterone and prostate cancer: from physiology to clinical implications.” European Urology, vol. 65, no. 1, 2014, pp. 115-123.
- U.S. Food and Drug Administration. “Jatenzo (testosterone undecanoate) capsules, for oral use – Highlights of Prescribing Information.” FDA, 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211445s000lbl.pdf.